Navigation Links
RenovoRx Announces FDA Clearance for Expanded Labeling
Date:3/30/2017

LOS ALTOS, Calif., March 30, 2017 /PRNewswire/ -- RenovoRx, manufacturer of the RenovoCath adjustable dual-balloon infusion catheter, today, announced it has received FDA 510(k) clearance to expand its indications for use to include the 'delivery of chemotherapeutics'. The RenovoCath device isolates segments of the peripheral vasculature, allowing physicians to deliver therapeutic agents in a more targeted fashion.

The new clearance expands the catheter's marketability for use with chemotherapeutics and potentially increases the number of diseases the RenovoCath may be used to treat. "This additional FDA indication marks yet another milestone for RenovoRx as we continue to work towards making our technology available to physicians to treat difficult diseases," says Shaun Bagai, RenovoRx's CEO. 

Studies show that the targeted delivery of chemotherapy may allow for higher concentrations of chemotherapy to reach the desired target, while potentially reducing overall side-effects typically associated with systemically delivered chemotherapy. The RenovoCath's dual balloons can be inflated independently and, unlike other catheters, the distance between the two balloons can be adjusted to isolate the desired treatment target. This adjustable length may allow for truly targeted therapy, while reducing washout of the therapy and potential systemic side effects. At his presentation at the November 2016 AIM/VEITH Symposium in New York, David Madoff, M.D., Professor of Radiology and Chief of Interventional Radiology at New York Presbyterian/Weill Cornell Medical Center and RenovoRx Advisory Board Member, described the versatility of the technology: "This catheter technology is different in that there's two balloons within a single catheter that can be inflated separately and has distinct lumens. You can adjust the length between the balloons to actually isolate and customize the area that you want to treat."

Dr. Madoff, who has used the catheter in several procedures has said that targeted delivery of drugs, like chemotherapy, has the potential to manage diseases that are otherwise difficult to treat and described the RenovoCath as the "ideal catheter for targeted delivery."

The RenovoCath is indicated for the isolation of blood flow and delivery of fluids, including diagnostic, chemotherapeutic and/or other therapeutic agents, to selected sites in the peripheral vasculature system.

About RenovoRx
RenovoRx (www.renovorx.com) is developing innovative solutions for targeted therapies. The ability to deliver therapeutic and/or chemotherapeutic materials at high concentration to specific vasculature, safely and without perfusion overlap to other regions, is a central paradigm of the company's technology. RenovoRx is based in Silicon Valley, California, and its top financial backers include Astia Angels, Golden Seeds, The Angels' Forum, The Halo Fund III, L.P., Plug and Play, and Rising Tide Fund/Portfolia.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/renovorx-announces-fda-clearance-for-expanded-labeling-300432020.html


'/>"/>
SOURCE RenovoRx
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Personal Genome Diagnostics Announces AACR Annual Meeting 2017 Presentations and Awards
2. Zansors Announces Issued Patent Protecting Adhesive for Wearable Health Sensors
3. BrainStorm Announces Financial Results for 2016 and Provides Business Update
4. ComplianceOnline Announces Medical Device Summit 2017 Venue and Speaker Line Up
5. Applied BioMath, LLC announces collaboration with Zymeworks Inc. for Clinical Trial Support in Oncology
6. Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis
7. Neurotrope, Inc. Announces Approval for Listing on the NASDAQ Capital Market
8. On World Tuberculosis Day 2017, American/Russian biotech partnership announces positive trial results for a new treatment of TB
9. SeraCare Life Sciences announces launch of industrys first multiplexed Inherited Cancer reference material
10. GlobeImmune Announces Majority Stock Sale
11. FACIT Announces Investment in Propellon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 10, 2019 , ... Thought ... with the appointment of Biofeedback Tech Ltd as its authorised distributor ... essential part of many therapeutic treatments and clinical assessment protocols to treat stress ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... human mesenchymal stem cells (MSC-EV) are able to incorporate into human CD34+ cells, ... test on mice, MSC-EVs also increased the cells’ ability to lodge into bone ...
(Date:5/31/2019)... ... May 30, 2019 , ... ... pleased to announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader ... Object exclusive ownership and commercialization rights to a full spectrum of botulinum neurotoxins, ...
(Date:5/15/2019)... ... May 16, 2019 , ... Emulsifiers ... result, food and beverage products rely on these ingredients to create stable quality ... label declarations. This paradigm shift triggers food formulators to seek out alternatives for ...
Breaking Biology Technology:
(Date:6/24/2019)... LOS ANGELES (PRWEB) , ... June 24, 2019 , ... ... every day with one of the four most common STDs: chlamydia, gonorrhea, trichomoniasis (or ... CDC reported that gay and bisexual African American men accounted for the largest ...
(Date:6/16/2019)... ... June 14, 2019 , ... Respected periodontist, ... the fifth annual Neodent World Congress. Attended by thousands of dental clinicians from ... advancements in the world of dentistry. The three-day event featured a team of ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... the first organization exclusively serving the end-to-end clinical and ancillary supply chain management ... as contract and medical research organizations, today announced it will sponsor a summer ...
Breaking Biology News(10 mins):